News | July 29, 2011

Oxygen Biotherapeutics, Aurum Biosciences Explore Imaging, Therapeutic Uses of Oxycyte PFC

Oxygen Biotherapeutics, Aurum Biosciences Explore Imaging, Therapeutic Uses of Oxycyte PFC

July 29, 2011 — Oxygen Biotherapeutics Inc. and privately held Aurum Biosciences Ltd. of Glasgow, Scotland, have signed a letter of intent (LOI) to conduct preclinical research for imaging and therapeutic intervention of acute ischemic stroke. Aurum, using Oxygen’s proprietary Oxycyte PFC (perfluorocarbon) emulsion in combination with Aurum’s proprietary Glasgow Oxygen Level Dependent (GOLD) magnetic resonance imaging (MRI) techniques, will conduct the research.  

The intent is to better delineate which tissue has been damaged from a stroke, and to determine the effectiveness of the treatment being provided to the model. Per the LOI, Aurum will seek funding for this research.

An ischemic stroke occurs when a blood vessel that carries oxygen and nutrients to the brain is blocked by a clot. When that happens, part of the brain cannot get the blood and, therefore, the oxygen it needs, so it starts to die. 

According to the American Stroke Association (ASA), approximately 795,000 Americans each year suffer a new or recurrent stroke. That means, on average, a stroke occurs every 40 seconds. Stroke kills more than 137,000 people a year in the United States alone and is the third leading cause of death behind diseases of the heart and cancer. On average, someone dies of stroke every four minutes. About 40 percent of stroke deaths occur in males, and 60 percent in females.

According to The Stroke Association, an estimated 150,000 people have a stroke in the United Kingdom each year, accounting for around 53,000 deaths annually. Stroke is the third most common cause of death in England and Wales, after heart disease and cancer. It accounts for 9 percent of all deaths in men and 13 percent of deaths in women in the United Kingdom.

For more information: www.oxybiomed.com

Related Content

Third FDA Clearance Announced for Zebra-Med's AI Solution for Brain Bleed Alerts
Technology | Artificial Intelligence | June 19, 2019
Zebra Medical Vision announced it has received its third U.S. Food and Drug Administration (FDA) 510(k) clearance for...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
SyMRI Software Receives FDA Clearance for Use With Siemens MRI Systems
Technology | Magnetic Resonance Imaging (MRI) | June 14, 2019
SyntheticMR announced U.S. Food and Drug Administration (FDA) clearance for clinical use of its SyMRI Image and SyMRI...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
Ann Arbor Startup Launches Augmented Reality MRI Simulator
Technology | Virtual and Augmented Reality | June 04, 2019
SpellBound, an Ann Arbor startup specializing in augmented reality (AR) tools for children in hospitals, has officially...

Photo courtesy of Philips Healthcare

Feature | Radiology Business | May 31, 2019 | By Arjen Radder
Change is a consistent theme in our world today, no matter where you look.
MRI Metal Artifact Reduction Poses Minimal Thermal Risk to Hip Arthroplasty Implants
News | Magnetic Resonance Imaging (MRI) | May 23, 2019
Clinical metal artifact reduction sequence (MARS) magnetic resonance imaging (MRI) protocols at 3 Tesla (3T) on hip...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res